Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

Abstract Background To compare visual function and structural improvements in pseudophakic eyes with diabetic macular oedema (DMO) treated with the 0.19mg Fluocinolone Acetonide (FAc) intravitreal implant (IluvienTM) in a ‘real world’ setting. Methods A single centre retrospective evaluation of pati...

Full description

Bibliographic Details
Main Authors: William Fusi-Rubiano, Chandoshi Mukherjee, Mark Lane, Marie D. Tsaloumas, Nicholas Glover, Andrej Kidess, Alastair K. Denniston, Helen E. Palmer, Avinash Manna, Rupal Morjaria
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Ophthalmology
Subjects:
Diabetic Macular Oedema
Iluvien
Diabetic Retinopathy
Fluocinolone Acetonide implant
Online Access:http://link.springer.com/article/10.1186/s12886-018-0726-1

Internet

http://link.springer.com/article/10.1186/s12886-018-0726-1

Similar Items